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OBJECTIVE: To assess the prevalence and burden of
ADHD in the Nordic countries. METHODS: Literature
databases were searched for publications relevant to the
study countries and keywords. The time frame was 1987
to 2002. The keywords were ADHD, DAMP, MBD, and
HKD. RESULTS: There were six prevalence studies in
children aged between six and nine years. The prevalence
rates of DAMP ranged between 2.8 and 7.1%. The preva-
lence rates of ADHD ranged between 3.7 and 7.1%.
Several smaller Finnish studies reported that children 
with MBD/ADHD often transfer to special education, 
or require additional teaching at school. Finnish and
Swedish studies found that 75–80% of children with
MBD/ADHD don’t complete high school. One Swedish
study showed that 11% of children with ADHD had full
sick pension at age 22. Finnish and Norwegian pub-
lications report that 38%–47% of children with
ADHD/MBD have no friends. Fifty-three percent of the
parents in a Norwegian study said their marital problems
were associated with the child’s MBD. Finnish and Nor-
wegian studies found that the child’s dysfunction caused
the family extra burden in daily activities and a change
of their work situation or time. Swedish, Danish, and
Finnish studies have shown that ADHD is associated with
long-term psychiatric consequences. In Denmark, 24% of
children with ADHD had been given a lifetime psy-
chiatric diagnosis at age 23. Finnish, Norwegian, and
Swedish studies have reported an over-representation 
of ADHD in prison populations. Moreover, children with
ADHD are especially exposed to sexual offences, and
commit such crimes more often than others. CONCLU-
SIONS: The Nordic data on prevalence of ADHD is in
concordance with international ﬁgures. Although some 
of the studies were small and not randomised, the 
results indicate that ADHD is associated with a great
burden for the affected children, their families, and the
environment.
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Compliance to treatment is a key success factor to reduce
hospitalisations in schizophrenic patients. Conventional
antipsychotics (e.g., haloperidol) are effective in reduc-
ing positive symptoms of schizophrenia, and can cause 
multiple side effects (extrapyramidal symptoms, tardive
dyskinesia). Atypical antipsychotics with daily oral
administration (risperidone, olanzapine, clozapine) show
improved efﬁcacy and tolerability compared to con-
ventional neuroleptics. Conventional depots have been
shown to increase compliance and reduce the risk of
relapse over oral conventional treatments. Long-acting
risperidone (LA-RIS), administered intramuscularly once
every two weeks, is the ﬁrst to combine the beneﬁts of a
long-acting formulation with those of an atypical antipsy-
chotic. OBJECTIVE: To assess cost-effectiveness of 
LA-RIS versus oral olanzapine (OLA) and haloperidol
decanoate (HAL-D) in recently diagnosed schizophrenic
patients in the perspective of the Italian National Health
care System (NHS). METHODS: A French decision tree
model was adapted to the Italian setting: outcome prob-
abilities and cost estimates were based on published 
data, and supplemented with expert opinion. Only direct
medical costs were considered. For LA-RIS (not yet mar-
keted in Italy), 3 different price hypotheses were tested
(€100–125–150/injection q2weeks). Effectiveness mea-
sures were relapse-free patients and patients maintained
on the same treatment for 2 years. RESULTS: LA-RIS was
found dominant versus HAL-D in all three hypotheses
tested. Versus OLA (10mg/day), LA-RIS cost-
effectiveness ratios ranged from dominance to a
maximum of €17,544/2 years per incremental relapse-free
patient. Sensitivity analysis showed that results were
robust over a wide range of parameters tested, including
variation of the daily dose of OLA to account for current
medical practice in Italy according to the results of the
RODOS papers (13.5mg/day). CONCLUSIONS: The
model indicates that in recently diagnosed patients, 
LA-RIS is cost-saving versus HAL-D and cost-saving/
cost-effective vs. OLA and should be preferred as a treat-
ment option over oral atypicals and conventional depots,
in the perspective of the Italian NHS.
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OBJECTIVES: The occurrence of dyslipidemia, glucose
intolerance and weight gain may lead to an increased 
risk for developing Diabetes and coronary heart disease
(CHD) during therapy with atypical antipsychotics. These
complications directly inﬂuence an antipsychotic agent’s
cost-effectiveness. One method for outcome assessment is
to capture these effects with the combined endpoint of
metabolic syndrome (MetS) and, using epidemiological
